AQST
Price
$3.40
Change
+$0.09 (+2.72%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
383.26M
42 days until earnings call
EVO
Price
$4.22
Change
+$0.02 (+0.48%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
2.77B
43 days until earnings call
Interact to see
Advertisement

AQST vs EVO

Header iconAQST vs EVO Comparison
Open Charts AQST vs EVOBanner chart's image
Aquestive Therapeutics
Price$3.40
Change+$0.09 (+2.72%)
Volume$13.95K
Capitalization383.26M
Evotec SE
Price$4.22
Change+$0.02 (+0.48%)
Volume$204
Capitalization2.77B
AQST vs EVO Comparison Chart in %
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. EVO commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and EVO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (AQST: $3.31 vs. EVO: $4.20)
Brand notoriety: AQST and EVO are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AQST: 67% vs. EVO: 77%
Market capitalization -- AQST: $383.26M vs. EVO: $2.77B
AQST [@Pharmaceuticals: Other] is valued at $383.26M. EVO’s [@Pharmaceuticals: Other] market capitalization is $2.77B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, both AQST and EVO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 5 TA indicator(s) are bullish while EVO’s TA Score has 5 bullish TA indicator(s).

  • AQST’s TA Score: 5 bullish, 5 bearish.
  • EVO’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, AQST is a better buy in the short-term than EVO.

Price Growth

AQST (@Pharmaceuticals: Other) experienced а +0.61% price change this week, while EVO (@Pharmaceuticals: Other) price change was +10.24% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.67%. For the same industry, the average monthly price growth was +80.48%, and the average quarterly price growth was +68.29%.

Reported Earning Dates

AQST is expected to report earnings on Aug 12, 2025.

EVO is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.67% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than AQST($383M). EVO YTD gains are higher at: 0.962 vs. AQST (-7.022). AQST has higher annual earnings (EBITDA): 1.18M vs. EVO (-63.26M). EVO has more cash in the bank: 619M vs. AQST (23.9M). AQST has less debt than EVO: AQST (33.3M) vs EVO (589M). EVO has higher revenues than AQST: EVO (821M) vs AQST (50.6M).
AQSTEVOAQST / EVO
Capitalization383M2.77B14%
EBITDA1.18M-63.26M-2%
Gain YTD-7.0220.962-730%
P/E RatioN/A476.19-
Revenue50.6M821M6%
Total Cash23.9M619M4%
Total Debt33.3M589M6%
FUNDAMENTALS RATINGS
AQST vs EVO: Fundamental Ratings
AQST
EVO
OUTLOOK RATING
1..100
8110
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
4350
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for EVO (93) in the null industry. This means that AQST’s stock grew somewhat faster than EVO’s over the last 12 months.

AQST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EVO (100) in the null industry. This means that AQST’s stock grew similarly to EVO’s over the last 12 months.

EVO's SMR Rating (94) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that EVO’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as EVO (50) in the null industry. This means that AQST’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that EVO’s stock grew significantly faster than AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTEVO
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 5 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 16 days ago
85%
Bullish Trend 6 days ago
68%
Declines
ODDS (%)
Bearish Trend 20 days ago
89%
Bearish Trend 12 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDGFX40.91N/A
N/A
Fidelity Dividend Growth
JDVRX23.21N/A
N/A
PGIM Jennison Value R
GSTIX14.27N/A
N/A
Goldman Sachs Strategic Growth Instl
KSMIX9.26N/A
N/A
Keeley Gabelli SMID Cap Value I
ACADX13.08N/A
N/A
American Century Emerging Markets G

AQST and

Correlation & Price change

A.I.dvisor indicates that over the last year, AQST has been loosely correlated with SCYX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then SCYX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.85%
SCYX - AQST
36%
Loosely correlated
-2.39%
DERM - AQST
31%
Poorly correlated
+0.56%
OGI - AQST
31%
Poorly correlated
N/A
TLRY - AQST
30%
Poorly correlated
+3.42%
CRDL - AQST
29%
Poorly correlated
-3.55%
More